A highly accomplished and collaborative leader with a track record of putting patients first, leading change, and delivering results, Andrea Geppert has played an instrumental part in Strongbridge Biopharma’s advances in rare neuromuscular and endocrine diseases.
Geppert worked on the launch of Keveyis, the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of primary periodic paralysis, then led the marketing effort for the commercial launch of Macrilen, the first and only FDA-approved oral test for the diagnosis of adult growth hormone deficiency.
Despite a four-month accelerated timeline, Geppert’s team set out to change the way the condition is diagnosed by making testing more accessible to HCPs and patients. The group’s Sherlock campaign, which highlighted detection and oral dosing in a simple and memorable way, tested off the charts in stopping power and message recall among endocrinologists.
A professional with a “deep commitment to improving the lives of patients,” Geppert recently earned an MBA in Healthcare Systems Management.
